Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi
Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
